FibroGen, Inc. FGEN
9.07 USD 0.00 (+0.00%)
Jan 12, 2026, 9:30 AM EST
9.02 Day range 9.21
52-week range unavailable
- YTD
- +3.30%
- 1 year
- -41.90%
Analyst view
Consensus: hold
Hold
Price target (mean) 10.00
Ratings (0m) 1 0 buy · 1 hold · 0 sell
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 1
- 1 month ago 2
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.20 | -0.20 – -0.20 | -0.57 | +64.9% | 24.91M | -8.2% | 1 |
| Next quarter | -0.10 | -0.10 – -0.10 | -0.33 | +69.7% | 0 | 0.0% | 1 |
| Current year | -0.86 | -0.86 – -0.86 | -2.79 | +69.2% | 177.85M | +20.4% | 1 |
| Next year | -0.38 | -0.38 – -0.38 | -0.86 | +55.8% | 166.15M | -6.6% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 8, 2023 | B of A Securities | Downgrade | Neutral | Underperform |
| Jun 27, 2023 | Goldman Sachs | Maintained | Sell | Sell |
| Jun 27, 2023 | Raymond James | Downgrade | Outperform | Market Perform |
| Jun 26, 2023 | B of A Securities | Downgrade | Buy | Neutral |
| Jun 26, 2023 | Stifel | Downgrade | Buy | Hold |
| Jun 26, 2023 | Raymond James | Downgrade | Outperform | Market Perform |
| Jun 26, 2023 | William Blair | Downgrade | Outperform | Market Perform |
| Jun 2, 2023 | Stifel | Upgrade | Hold | Buy |
| Feb 28, 2023 | Cowen & Co. | Maintained | — | Market Perform |
| Feb 23, 2023 | Goldman Sachs | Maintained | — | Sell |
| Feb 21, 2023 | Goldman Sachs | Maintained | — | Sell |
| Jan 31, 2023 | William Blair | Upgrade | Market Perform | Outperform |
| Jan 26, 2023 | Raymond James | Upgrade | Market Perform | Outperform |
| Jan 5, 2023 | B of A Securities | Upgrade | Neutral | Buy |
| Nov 8, 2022 | Goldman Sachs | Maintained | — | Sell |
| May 24, 2022 | Goldman Sachs | Maintained | — | Sell |
| Mar 1, 2022 | Goldman Sachs | Maintained | — | Sell |
| Sep 22, 2021 | Goldman Sachs | Downgrade | Neutral | Sell |
| Aug 20, 2021 | Raymond James | Upgrade | Underperform | Market Perform |
| Aug 10, 2021 | SVB Leerink | Maintained | — | Outperform |
| Jul 16, 2021 | B of A Securities | Downgrade | Buy | Neutral |
| Jul 16, 2021 | Stifel | Downgrade | Buy | Hold |
| Apr 7, 2021 | Mizuho | Downgrade | Buy | Neutral |
| Apr 7, 2021 | SVB Leerink | Maintained | — | Outperform |
| Apr 7, 2021 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Apr 7, 2021 | JP Morgan | Upgrade | Underweight | Neutral |
| Mar 31, 2021 | B of A Securities | Upgrade | Neutral | Buy |
| Mar 2, 2021 | SVB Leerink | Maintained | — | Outperform |
| Mar 2, 2021 | Jefferies | Downgrade | Buy | Hold |
| Feb 1, 2021 | HC Wainwright & Co. | Initiated | — | Buy |